BEST-IN-CLASS ENZYMES

Using novel enzyme compounds Oxidien develops superior treatments for

secondary hyperoxaluria to ultimately prevent kidney stone disease.

Download Oxidien’s Latest Non-confidential Deck

  • Enter your Email to download Oxidien’s Latest Non-confidential Deck

PROUD TO PARTNER WITH:

Unmet Need

Secondary hyperoxaluria is a disease with significant unmet medical need. Patients demonstrate wide ranging severity, from manageable symptoms to severe and chronic complications.

There are two types of Secondary (2°) Hyperoxaluria : Idiopathic Hyperoxaluria (IH) and Enteric Hyperoxaluria (EH) 1, 2, 3 .

IH is the most common type, and mostly observed in individuals with calcium oxalate kidney stones1, 4, 5. EH is partly caused by an underlying gastrointestinal complication associated with a malabsorption of oxalate. In these patients, oxalate becomes more available for absorption 2 , which can cause severe kidney damage and can lead to end-stage renal failure.

Oxidien estimates that there are 200,000 – 250,000 patients with enteric hyperoxaluria in the U.S. alone and  4 – 5 million people that are hyperoxaluric stone formers in the general U.S. population. For more information on the unmet need and the market in the U.S. and worldwide.

Novel and Clinically Studied Enzyme

OX-1

OX-1 is a novel enzyme to treat hyperoxaluria that was developed with the support of multiple National Institute of Health (NIH) Small Business Innovation Research (SBIR) Grants. It exhibits a broad pH-activity profile and a superior stability and activity in the stomach. OX-1 has demonstrated biological effect in healthy volunteers and is the first product to demonstrate meaningful effect in subjects with dietary induced hyperoxaluria at upper limit of normal.

A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Utilizing Orally Administered Oxalate Decarboxylase (OxDC) To Reduce Urinary Oxalate.

With its clinically studied product and
cost-efficient and scaled manufacturing process, Oxidien is poised to generate meaningful data in enteric hyperoxaluria patients with an economically realistic approach for the benefit of patients
world-wide.

Helena Cowley, Co-founder and CEO

Meet Us Here

For details on what we are up to and where we are, please check out our Events and Presentations page.

Latest News

Oxidien Pharmaceuticals, LLC

747 SW 2nd Avenue, IMB 57
Gainesville, FL 32601

Phone